Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, in a new study.
Huseyin Naci,assistant professor of health policy a the London School of Economics joins us to talk about why potential bias may mean potential exaggeration of treatment effects, and could be costing our health systems a great deal of money.
Read the full research:
https://www.bmj.com/content/366/bmj.l5221
Listen on apple podcasts:
https://podcasts.apple.com/gb/podcast/the-bmj-podcast/id283916558?mt=2&app=podcast
Medicine and Science from The BMJ